The specific aim of the Gabapentin for the Relief of Idiopathic Subjective Tinnitus Trial is
to assess the therapeutic benefit of Gabapentin (Neurontin®) for subjective idiopathic
troublesome tinnitus. We employed a double-blind placebo-controlled randomized clinical trial
design to assess the efficacy of Gabapentin. Adults, between the ages of 18 and 70 with
idiopathic, subjective, troublesome, unilateral or bilateral, non-pulsatile tinnitus of 6
month's duration or greater and score of 38 or greater on the Tinnitus Handicap Inventory
were enrolled.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
National Institute on Deafness and Other Communication Disorders (NIDCD)